Register for access to the Endpoints hub and theater and pick up your credentials/badges. All attendees require a name badge worn at all times.

Merck delivered oncology's biggest success of the 2010s. But what comes next? We'll discuss Merck's foray into immunology, its priorities for 2024, the IRA's influence on R&D choices and much more.

After a decade of progress in oncology, there's still much to be done. Our experts will talk through where cancer innovation is going, new targets and the data we'll be watching through the rest of the 2020s.

How does a pharma transaction get done? We'll hear from AstraZeneca about several recent deals and the strategic approach behind them.

It wasn't easy to raise capital in 2023. But some startups not only did so, they thrived. Get a candid look at the pitch, the technology and the promise behind one of last year's high-profile rounds.

Our panelists have seen the worst, and made it through to the other side. Join us for downturn survival school as our panelists talk about what sets apart the ones who make it through tough times.

Marianne De Backer was well known as one of the industry’s top dealmakers when she was tapped for the CEO’s job at Vir Biotechnology. Now the former Bayer and J&J exec has a broad remit and a host of objectives on R&D in infectious diseases — and beyond. She’ll sit down with Endpoints founding editor John Carroll to talk about being the CEO, leadership in biotechnology and what plans she’s making as we enter 2024.

Join us for a look at how AI, machine learning and generative technologies are actually being applied inside drugmakers' labs. We'll explore how new technologies are being used, their implications, how they intersect with regulatory and IP issues and how this fast-changing field is likely to evolve.

Walgreens hired a new CEO in October 2023. In an exclusive conversation with Endpoints News, the pharmacy giant's new leader Tim Wentworth breaks down what the company has in store for 2024.

Merdad Parsey will join Executive Editor Drew Armstrong for a discussion about the future of HIV treatment and prevention, the company's goals in the oncology space and more.

Our journalists wrap up by sharing their takeaways from the conference and their best guesses for the year ahead.